31.1 C
New York
Saturday, June 13, 2026

Tag: equity

MoneySimpler Launches New AI-Powered Trading Automation App to Streamline Cross-Asset Workflows in 2026

MoneySimpler, a leading financial technology developer specialising in automated strategy workflows, today announced the official launch and global expansion of its 2026 AI-powered trading automation ecosystem. Built to support retail investors seeking to capture international market opportunities more systematically, the newly deployed framework integrates cryptocurrency, forex, and equity tracking into a unified smart dashboard to maximize data management efficiency for users worldwide.
MoneySimpler, a leading financial technology developer specialising in automated strategy workflows, today announced the official launch and global expansion of its 2026 AI-powered trading automation ecosystem. Built to support retail investors seeking to capture international market opportunities more systematically, the newly deployed framework integrates cryptocurrency, forex, and equity tracking into a unified smart dashboard to maximize data management efficiency for users worldwide.

Scout Clean Energy Moves into New Ottawa Office and Celebrates Trail Road BESS Construction Start

Scout Clean Energy celebrated the opening of its Ottawa office and the launch of construction on its Trail Road Battery Energy Storage System.

Mt. Hood Tiny House Village Celebrates 10-Year Anniversary

Open House Celebration at Mt. Hood Village Resort on June 12 & 13WELCHES, Ore., June 10, 2026 /PRNewswire/ -- Mt. Hood Tiny House Village is...

OZOP Energy Solutions, Inc. Highlights Southern California Market Entry Through Tenace Consulting as Regional Distribution Partnership

WARWICK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OTC: OZSC, the “Company”) today announced Ballislife Drink Inc.’s entry into the Southern California market through Varon Corp’s U.S. subsidiary, Varon USA, supported by the appointment of Tenace Consulting (Tenace) as its regional distribution partner. Ozop and Varon Corp are currently completing customary pre-closing conditions in connection with the previously announced transaction with OZOP.

Hemlo Mining Corp. Announces Graduation to the Toronto Stock Exchange

Trading to begin at market open on Monday, June 15, 2026TORONTO, June 10, 2026 /CNW/ - Hemlo Mining Corp. (TSXV: HMMC) (OTCQX: HMMCF) (the...

Dancewear Market to Reach $2.2 billion, Globally, by 2035 at 4.8% CAGR: Allied Market Research

The dancewear market is witnessing steady adoption across dance academies, professional dance companies, fitness centers, educational institutions, performance arts organizations, and individual consumers due...

NBPE Announces Transaction in Own Shares

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

ING rolls out global subscription banking model

ING rolls out global subscription banking model

High Arctic Announces Management Changes

High Arctic Announces Management Changes

CLINICIANS AT THREE OF WASHINGTON’S LARGEST HEALTHCARE SYSTEMS FILE TO UNIONIZE, CITING PATIENT CARE CONCERNS

SEATTLE, June 9, 2026 /PRNewswire/ -- Two hundred and fifty nurse practitioners and physician assistants working across multiple clinic locations at Fred Hutchinson Cancer...

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, today announced the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor

HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on...

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEquity